Prevention of immune-mediated transfusion-related acute lung injury; from bloodbank to patient

Current Pharmaceutical Design

Volumn 18, Issue 22, 2012, Pages 3241-3248

  Múller, Marcella C A ^a   Porcelijn, Leendert ^b   Vlaar, Alexander P J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Sanquin Diagnostiek   (Netherlands)

Author keywords

HLA and HNA antibody; Prevention; Transfusion related lung injury

Indexed keywords

HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR4 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; TRANEXAMIC ACID;

AGGLUTINATION TEST; ANTIBODY SCREENING; ARTIFICIAL VENTILATION; BLOOD BANK; BLOOD CLOTTING TEST; BLOOD GROUP TYPING; BLOOD SAFETY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; FLOW CYTOMETRY; HEART SURGERY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNITY; IMMUNOFLUORESCENCE TEST; INJURY; LYMPHOCYTE; MORBIDITY; MORTALITY; MULTIPARA; NEUTROPHIL; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS; SYSTEMATIC REVIEW; THROMBOCYTOPHERESIS; TRANSFUSION RELATED ACUTE LUNG INJURY; VENOUS STASIS;

EID: 84862548067     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023241     Document Type: Review

References (95)

1. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005; 19: 2-31.
2. Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev 2004; 18: 184-8.
3. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44: 1774-89.
4. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006; 20: 273-82.
5. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007; 176: 886-91.
6. Rana R, Fernandez-Perez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion 2006; 46: 1478-83.
7. Vlaar AP, Binnekade JM, Prins D, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: A nested case-control study. Crit Care Med 2010; 38: 771-8.
8. Li G, Kojicic M, Reriani MK, et al. Long-term survival and quality of life after transfusion-associated pulmonary edema in critically ill medical patients. Chest 2010; 137: 783-9.
9. Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007; 136: 788-99.
10. Silliman CC. The two-event model of transfusion-related acute lung injury. Crit Care Med 2006; 34: S124-S131.
11. Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis 1983; 128: 185-9.
12. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002; 287: 1968-71.
13. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25: 573-7.
14. Endres RO, Kleinman SH, Carrick DM, et al. Identification of specificities of antibodies against human leukocyte antigens in blood donors. Transfusion 2010; 50: 1749-60.
15. Middelburg RA, Porcelijn L, Lardy N, Briet E, Vrielink H. Prevalence of leucocyte antibodies in the Dutch donor population. Vox Sang 2010
16. Reil A, Keller-Stanislawski B, Gunay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008; 95: 313-7.
17. Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion 2010
18. Moritz E, Norcia AM, Cardone JD, et al. Human neutrophil alloantigens systems. An Acad Bras Cienc 2009; 81: 559-69.
19. Muschter S, Berthold T, Greinacher A. Developments in the definition and clinical impact of human neutrophil antigens. Curr Opin Hematol 2011; 18: 452-60.
20. De HM, Kleijer M, Van ZR, Roos D, von dem Borne AE. Neutrophil Fc gamma RIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families. Blood 1995; 86: 2403-13.
21. Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009; 49: 440-52.
22. van Stein D, Beckers EA, Sintnicolaas K, et al. Transfusion-related acute lung injury reports in the Netherlands: an observational study. Transfusion 2010; 50: 213-20.
23. Bierling P, Bux J, Curtis B, et al. Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibodymediated transfusion-related acute lung injury. Vox Sang 2009; 96: 266-9.
24. Verheugt FW, von dem Borne AE, Decary F, Engelfriet CP. The detection of granulocyte alloantibodies with an indirect immunofluorescence test. Br J Haematol 1977; 36: 533-44.
25. Jiang AF, Lalezari P. A micro-technique for detection of leukocyte agglutinins. J Immunol Methods 1975; 7: 103-8.
26. Bux J, Kober B, Kiefel V, Mueller-Eckhardt C. Analysis of granulocyte-reactive antibodies using an immunoassay based upon monoclonal-antibody-specific immobilization of granulocyte antigens. Transfus Med 1993; 3: 157-62.
27. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-6.
28. Shot Annual report 2005: www.shotuk.org. SHOT annual report 2005
29. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med 2007; 33 Suppl 1: 17-21.
30. Funk MB, Guenay S, Lohmann A, et al. Benefit of transfusion- related acute lung injury risk-minimization measures - German haemovigilance data (2006-2010). Vox Sang 2011
31. Knowles S, Cohen H. The 2010 Annual SHOT report (2011). 2011
32. Schipperus MR, Wiersum-Osselton JC. On behalf of the TransfusieReacties In Patienten (TRIP) Steering Group. TRIP rapport 2009 hemovigilantie. www.tripnet.nl. 2009
33. Win N, Chapman CE, Bowles KM, et al. How much residual plasma may cause TRALI? Transfus Med 2008; 18: 276-80.
34. Kelher MR, Masuno T, Moore EE, et al. Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. Blood 2009; 113: 2079-87.
35. Takahashi D, Fujihara M, Azuma H, et al. Stimulation of human neutrophils with sera containing HLA Class I alloantibody causes preferential degranulation of azurophilic granules and secretory vesicles. Vox Sang 2010; 98: 560-6.
36. Strait RT, Hicks W, Barasa N, et al. MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice. J Exp Med 2011
37. Bux J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sang 2011; 100: 122-8.
38. Nishimura M, Hashimoto S, Takanashi M, Okazaki H, Satake M, Nakajima K. Role of anti-human leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury. Transfus Med 2007; 17: 129-34.
39. Sachs UJ. Recent insights into the mechanism of transfusion- related acute lung injury. Curr Opin Hematol 2011; 18: 436-42.
40. Sachs UJ, Wasel W, Bayat B, et al. Mechanism of transfusion- related acute lung injury induced by HLA class II antibodies. Blood 2011; 117: 669-77.
41. Décary F. A look at HLA antisera in the indirect immuno- fluorescence technique (LIFT). In Histocompatibility testing. 1975: 380-90.
42. Uboldi de CM, Pratico L, Curtoni ES. Comparison of different techniques for detection of anti-HLA antibodies in sera from patients awaiting kidney transplantation. Eur J Immunogenet 2002; 29: 379-82.
43. Phelan DL, Rodey GE, Anderson CB. The development and specificity of antiidiotypic antibodies in renal transplant recipients receiving single-donor blood transfusions. Transplantation 1989; 48: 57-60.
44. Terasaki PI, MCCLELLAND JD. MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS. Nature 1964; 204: 998-1000.
45. Pei R, Lee J, Chen T, Rojo S, Terasaki PI. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 1999; 60: 1293-302.
46. Wahrmann M, Exner M, Haidbauer B, et al. [C4d]FlowPRA screening--a specific assay for selective detection of complementactivating anti-HLA alloantibodies. Hum Immunol 2005; 66: 526-34.
47. Colombo MB, Haworth SE, Poli F, et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 2007; 72: 465-71.
48. Bray RA, Gebel HM. Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant 2009; 14: 392-7.
49. Claas FH, Doxiadis II. Human leukocyte antigen antibody detection and kidney allocation within Eurotransplant. Hum Immunol 2009; 70: 636-9.
50. Doxiadis II, Roelen D, Claas FH. Mature wines are better: CDC as the leading method to define highly sensitized patients. Curr Opin Organ Transplant 2010
51. Zoet YM, Brand-Schaaf SH, Roelen DL, Mulder A, Claas FH, Doxiadis II. Challenging the golden standard in defining donor- specific antibodies: does the solid phase assay meet the expectations? Tissue Antigens 2011; 77: 225-8.
52. Hashimoto S, Nakajima F, Kamada H, et al. Relationship of donor HLA antibody strength to the development of transfusion-related acute lung injury. Transfusion 2010
53. Kakaiya RM, Triulzi DJ, Wright DJ, et al. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion 2010; 50: 1328-34.
54. Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49: 1825-35.
55. Palfi M, Berg S, Ernerudh J, Berlin G. A randomized controlled trial oftransfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? Transfusion 2001; 41: 317-22.
56. Vamvakas EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLAalloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med Rev 1998; 12: 258-70.
57. Gleichmann H, Breininger J. Over 95 per cent sensitization against allogeneic leukocytes following single massive blood transfusion. Vox Sang 1975; 28: 66-73.
58. Lubenko A, Rodi KM. The detection by enzyme-linked immunosorbent assays of non-complement-fixing HLA antibodies in transfusion medicine. Transfusion 1998; 38: 41-4.
59. Marik PE, Corwin HL. Acute lung injury following blood transfusion: expanding the definition. Crit Care Med 2008; 36: 3080-4.
60. Vlaar AP, Binnekade JM, Schultz MJ, Juffermans NP, Koopman MM. Preventing TRALI: ladies first, what follows? Crit Care Med 2008; 36: 3283-4.
61. Wiersum-Osselton JC, Middelburg RA, Beckers EA, et al. Male- only fresh-frozen plasma for transfusion-related acute lung injury prevention: before-and-after comparative cohort study. Transfusion 2010
62. Wright SE, Snowden CP, Athey SC, et al. Acute lung injury after ruptured abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma. Crit Care Med 2008; 36: 1796-802.
63. Vlaar AP, Wortel K, Binnekade JM, et al. The practice of reporting transfusion-related acute lung injury: a national survey among clinical and preclinical disciplines. Transfusion 2009; 50: 443-51.
64. Curtis BR, McFarland JG. Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies. Crit Care Med 2006; 34: S118-S123.
65. Keller-Stanislawski B, Reil A, Gunay S, Funk MB. Frequency and severity of transfusion-related acute lung injury--German haemovigilance data (2006-2007). Vox Sang 2010; 98: 70-7.
66. Wiersum-Osselton JC, Porcelijn L, van Stein D., Vlaar AP, Beckers EA, Schipperus MR. [Transfusion-related acute lung injury (TRALI) in the Netherlands in 2002-2005]. Ned Tijdschr Geneeskd 2008; 152: 1784-8.
67. Annual Hemovigilance Report Swissmedic 2008, http://www.swissmedic.ch. 2011
68. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007; 47: 599-607.
69. Lin Y, Saw CL, Hannach B, Goldman M. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion 2011
70. Carrick DM, Norris PJ, Endres RO, et al. Establishing assay cutoffs for HLA antibody screening of apheresis donors. Transfusion 2011; 51: 2092-101.
71. Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 2005; 45: 1628-31.
72. Flesland O, Seghatchian J, Solheim BG. The Norwegian Plasma Fractionation Project--a 12 year clinical and economic success story. Transfus Apher Sci 2003; 28: 93-100.
73. Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost- effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003; 85: 88-95.
74. Kleinman S, Grossman B, Kopko P. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States. Transfusion 2010; 50: 1312-21.
75. Rios JA, Schlumpf KS, Kakaiya RM, et al. Blood donations from previously transfused or pregnant donors: a multicenter study to determine the frequency of alloexposure. Transfusion 2011; 51: 1197-206.
76. Ozier Y, Muller JY, Mertes PM, et al. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. Transfusion 2011; 51: 2102-10.
77. Vamvakas EC. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009; 49: 2743-58.
78. Eder AF, Herron RM, Jr., Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010; 50: 1732-42.
79. Kram R, Loer SA. Transfusion-related acute lung injury: lack of recognition because of unawareness of this complication? Eur J Anaesthesiol 2005; 22: 369-72.
80. Gajic O, Rana R, Mendez JL, et al. Acute lung injury after blood transfusion in mechanically ventilated patients. Transfusion 2004; 44: 1468-74.
81. Vlaar AP, Hofstra JJ, Determann RM, et al. The incidence, risk factors, and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: a prospective nested case-control study. Blood 2011; 117: 4218-25.
82. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342: 1301-8.
83. Vlaar AP, Wolthuis EK, Hofstra JJ, et al. Mechanical ventilation aggravates transfusion-related acute lung injury induced by MHC-I class antibodies. Intensive Care Med 2010;36: 879-87.
84. Yilmaz M, Keegan MT, Iscimen R, et al. Toward the prevention of acute lung injury: protocol-guided limitation of large tidal volume ventilation and inappropriate transfusion. Crit Care Med 2007; 35: 1660-6.
85. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-17.
86. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
87. Walsh TS, Stanworth SJ, Prescott RJ, Lee RJ, Watson DM, Wyncoll D. Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units. Crit Care Med 2010; 38: 1939-46.
88. Rana R, Afessa B, Keegan MT, et al. Evidence-based red cell transfusion in the critically ill: quality improvement using computerized physician order entry. Crit Care Med 2006; 34: 1892-7.
89. Schochl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14: R55.
90. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: 312-9.
91. Wolff J, Brendel C, Fink L, Bohle RM, Kissel K, Bux J. Lack of NB1 GP (CD177/HNA-2a) gene transcription in NB1 GP- neutrophils from NB1 GP-expressing individuals and association of low expression with NB1 gene polymorphisms. Blood 2003; 102: 731-3.
92. Kissel K, Scheffler S, Kerowgan M, Bux J. Molecular basis of NB1 (HNA-2a, CD177) deficiency. Blood 2002; 99: 4231-3.
93. Vlaar AP, Hofstra JJ, Determann RM, et al. The incidence, risk factors and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: a prospective nested case control study. Blood 2011; 117: 4218-25.
94. Nakazawa H, Ohnishi H, Okazaki H, et al. Impact of fresh-frozen plasma from male-only donors versus mixed-sex donors on postoperative respiratory function in surgical patients: a prospective case-controlled study. Transfusion 2009; 49: 2434-41.
95. Toy P, Gajic O, Bacchetti P, et al. Transfusion related acute lung injury: incidence and risk factors. Blood 2011; Epub ahead of print.